The Experts below are selected from a list of 15 Experts worldwide ranked by ideXlab platform
Iwona Kątnikprastowska - One of the best experts on this subject based on the ideXlab platform.
-
terminal monosaccharide expression on amniotic glycoproteins as biomarkers of Fetus Maturity
Biochemical Society Transactions, 2011Co-Authors: Magdalena Orczykpawilowicz, Iwona KątnikprastowskaAbstract:Glycotypes, particularly those that terminate with sialic acid and fucose are known to play a fundamental role in human development, during implantation, growth and differentiation of fetal tissues. The present review describes changes in the exposition of terminal sialic acid and fucose isoforms in the amniotic fluid glycoconjugates, α1-acid glycoprotein and fibronectin during critical stages of pregnancy, i.e. second and third trimester, perinatal period, delivery and post-date pregnancy. The distinct amniotic glycoforms are suggested to be implicated in regulatory processes to ensure homoeostasis during pregnancy and to protect the Fetus. These may have the potential of becoming additional laboratory makers in obstetrics to monitor pregnancy. AF (amniotic fluid) contains bioactive molecules AFprotectstheFetusphysicallyandbiochemicallyandassists in its development. AF resides in the amniotic cavity that is lined by the amnion and chorion. The amniotic sac grows and begins to fill, mainly with water, at approx. 2 weeks after fertilization. In the 12th week of pregnancy, the AF contains proteins, carbohydrates, lipids and phospholipids, all of which aid in the growth of the Fetus. AF is produced by exudation of fluid through the skin of the Fetus up to the 14th week of pregnancy, when keratinization of the skin occurs. During the 8th–11th week of pregnancy, the Fetus beginstoswallowandurinate,whichiswhytheamnioticfluid consistsoffetalurineatthelatestagesofgestation.Cellsfrom the amnion and chorion layers secrete proteins into the AF. The protein and metabolite composition of AF varies throughout gestation [1]. The growth factors, innate immunity molecules and serum components in AF are believed to be involved in growth, development and protection of the Fetus against infection. These functional biomolecules are mainly glycoproteins, several of which have been shown to exertimmunomodulatoryeffects.AmongthemareAGP(α1acid glycoprotein), glycodelin A and transferrin, which carry sialyl-Lewis x glycotopes on some of their N-linked glycan structures. Furthermore, they are known to act as inhibitors of E-selectin-mediated cell adhesion during acute inflammation [2–6]. The glycans that contain α1,3-linked fucose may modulate the processes of the acute-phase reaction, whereas those with α1,2-linked fucose may block the binding of α1,2fucose-dependent bacteria to fetal tissue [5]. AF is a significant contributor to fetal health and constitutesapotentialrichsourceofbiomarkersfordiagnosis
Magdalena Orczykpawilowicz - One of the best experts on this subject based on the ideXlab platform.
-
terminal monosaccharide expression on amniotic glycoproteins as biomarkers of Fetus Maturity
Biochemical Society Transactions, 2011Co-Authors: Magdalena Orczykpawilowicz, Iwona KątnikprastowskaAbstract:Glycotypes, particularly those that terminate with sialic acid and fucose are known to play a fundamental role in human development, during implantation, growth and differentiation of fetal tissues. The present review describes changes in the exposition of terminal sialic acid and fucose isoforms in the amniotic fluid glycoconjugates, α1-acid glycoprotein and fibronectin during critical stages of pregnancy, i.e. second and third trimester, perinatal period, delivery and post-date pregnancy. The distinct amniotic glycoforms are suggested to be implicated in regulatory processes to ensure homoeostasis during pregnancy and to protect the Fetus. These may have the potential of becoming additional laboratory makers in obstetrics to monitor pregnancy. AF (amniotic fluid) contains bioactive molecules AFprotectstheFetusphysicallyandbiochemicallyandassists in its development. AF resides in the amniotic cavity that is lined by the amnion and chorion. The amniotic sac grows and begins to fill, mainly with water, at approx. 2 weeks after fertilization. In the 12th week of pregnancy, the AF contains proteins, carbohydrates, lipids and phospholipids, all of which aid in the growth of the Fetus. AF is produced by exudation of fluid through the skin of the Fetus up to the 14th week of pregnancy, when keratinization of the skin occurs. During the 8th–11th week of pregnancy, the Fetus beginstoswallowandurinate,whichiswhytheamnioticfluid consistsoffetalurineatthelatestagesofgestation.Cellsfrom the amnion and chorion layers secrete proteins into the AF. The protein and metabolite composition of AF varies throughout gestation [1]. The growth factors, innate immunity molecules and serum components in AF are believed to be involved in growth, development and protection of the Fetus against infection. These functional biomolecules are mainly glycoproteins, several of which have been shown to exertimmunomodulatoryeffects.AmongthemareAGP(α1acid glycoprotein), glycodelin A and transferrin, which carry sialyl-Lewis x glycotopes on some of their N-linked glycan structures. Furthermore, they are known to act as inhibitors of E-selectin-mediated cell adhesion during acute inflammation [2–6]. The glycans that contain α1,3-linked fucose may modulate the processes of the acute-phase reaction, whereas those with α1,2-linked fucose may block the binding of α1,2fucose-dependent bacteria to fetal tissue [5]. AF is a significant contributor to fetal health and constitutesapotentialrichsourceofbiomarkersfordiagnosis
Jasna Opalic - One of the best experts on this subject based on the ideXlab platform.
-
Quantitative analysis of lamellar bodies in amniotic fluid as fetal pulmonary Maturity indicator
Vojnosanitetski Pregled, 2009Co-Authors: Vesna Ljubic, Nebojsa Radunovic, Aleksandar Stefanovic, Jasna OpalicAbstract:Background/Aim. Although lamellar bodies have been the center of interest over the last years, the published results of fetal pulmonary Maturity determination according to their concentration in amniotic fluid are controversial. The aim of this study was to determine the significance of lamellar bodies, as well as the ratio lecithin/sphingomyelin (L/S) in amniotic fluid for the assessment of fetal pulmonary Maturity. Methods. This prospective 2-year study included 102 female examinees, ranging from 17 to 44 years of age, in whom lamellar bodies concentrations in amniotic fluid were determined to check the efficacy of the applied therapy for obtaining arteficial fetal pulmonary Maturity. The shake test was applied as a comparative test for determining a quantitative L/S ratio. To determine a Fetus Maturity and development stage we followed up biparietal diameter, abdominal circumference, femure length, ponderal index at birth and body mass. Results. Out of a total of 102 amniocenteses within a period from 26th to 40th gestation week only 70 results were considered due to 32 unknown neonatal outcomes. Biparietal diameter was 224-362 mm, femur length 56 - 78 mm, ponderal index 1.22-2.84, Fetus body mass 1300- 4 350 g. There was found a significant relation between gestation age and lamellar bodies concentration (R = 0.396398, p < 0.01), as well as between gestation age and the ratio L/S (R = 0.691297, p < 0.01). Also, there was a significant correlation of lamellar bodies concentration to the ratio L/S determined (R = 0.493609, p < 0.01). Conclusion. Determination of lamellar bodies concentration values is a reliable method to confirm fetal pulmonary Maturity.
Vesna Ljubic - One of the best experts on this subject based on the ideXlab platform.
-
Quantitative analysis of lamellar bodies in amniotic fluid as fetal pulmonary Maturity indicator
Vojnosanitetski Pregled, 2009Co-Authors: Vesna Ljubic, Nebojsa Radunovic, Aleksandar Stefanovic, Jasna OpalicAbstract:Background/Aim. Although lamellar bodies have been the center of interest over the last years, the published results of fetal pulmonary Maturity determination according to their concentration in amniotic fluid are controversial. The aim of this study was to determine the significance of lamellar bodies, as well as the ratio lecithin/sphingomyelin (L/S) in amniotic fluid for the assessment of fetal pulmonary Maturity. Methods. This prospective 2-year study included 102 female examinees, ranging from 17 to 44 years of age, in whom lamellar bodies concentrations in amniotic fluid were determined to check the efficacy of the applied therapy for obtaining arteficial fetal pulmonary Maturity. The shake test was applied as a comparative test for determining a quantitative L/S ratio. To determine a Fetus Maturity and development stage we followed up biparietal diameter, abdominal circumference, femure length, ponderal index at birth and body mass. Results. Out of a total of 102 amniocenteses within a period from 26th to 40th gestation week only 70 results were considered due to 32 unknown neonatal outcomes. Biparietal diameter was 224-362 mm, femur length 56 - 78 mm, ponderal index 1.22-2.84, Fetus body mass 1300- 4 350 g. There was found a significant relation between gestation age and lamellar bodies concentration (R = 0.396398, p < 0.01), as well as between gestation age and the ratio L/S (R = 0.691297, p < 0.01). Also, there was a significant correlation of lamellar bodies concentration to the ratio L/S determined (R = 0.493609, p < 0.01). Conclusion. Determination of lamellar bodies concentration values is a reliable method to confirm fetal pulmonary Maturity.
Keng Shen - One of the best experts on this subject based on the ideXlab platform.
-
Management of invasive cervical cancer in pregnancy: clinical analysis of 13 cases
Zhonghua fu chan ke za zhi, 2012Co-Authors: Guo Q, Shan Y, Jiaxin Yang, Liu Jt, Cheng Nh, Huang Hf, Pan Ly, Jinghe Lang, Keng ShenAbstract:To analyze the clinical characteristics and assess the outcome of treatment for cervical cancer during pregnancy. A cohort of 13 patients with cervical cancer diagnosed during pregnancy from January 2001 to September 2011 in Peking Union Medical College Hospital (PUMCH) was retrospectively studied. Clinical information, gestational age at diagnosis, treatment options and maternal and child outcomes were collected and analyzed. Thirteen patients out of 2030 cases of invasive cervical cancer were diagnosed during pregnancy with an incidence of 0.64% (13/2030). The Mean gestational age at diagnosis of 13 patients is 21(+6) weeks. Two cases were diagnosed during the first trimester, 8 cases at second trimester and 3 cases at third trimester respectively. Vaginal bleeding during the pregnancy was main clinical manifestation presented in 8 patients and all thirteen cases were diagnosed by biopsy with pathological types of squamous cell carcinoma in 10 cases. The International Federation of Gynecology and Obstetrics (FIGO) stage was I in eleven cases and stage II in two cases. Six patients of them received treatment promptly after diagnosis. The other 7 patients had delayed treatment with mean diagnosis-treatment interval time of 65 days due to fertility reasons, who ended pregnancy by cesarean section at mean gestational age of 34(+6) weeks, two of them received chemotherapy with cisplatin + fluorouracil (PF) or cisplatin respectively before the end of the pregnancy, while the one with PF chemotherapy experienced neonatal death. The rest 6 neonatal outcomes were good. As follow-up of 13 cases: 11 cases in stage I received surgical treatment, and two of which had recurrence respectively, 15 months and 7 months post surgery, and one case had died. One case of Stage II patients died and one had recurrence after 53 months after radiotherapy. The recurrence rate in 13 cases was 3/13 and the mortality rate was 2/13. Most cases of cervical cancer diagnosed during pregnancy were in early FIGO stage. For those patients diagnosed in late pregnancy with strong fertility demand, considering delayed treatment according to FIGO stage of the disease and Fetus Maturity is appropriate. Chemotherapy during pregnancy may cause neonatal complications.